x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Mar 18, 2017 12:54 PM ET

Johnson & Weaver, LLP Files Class Action Suit against Natus Medical Incorporated

Legal Newswire iCrowdNewswire - Mar 18, 2017

 

SAN DIEGO — Shareholder rights law firm Johnson & Weaver, LLP announced that a class action had been filed on behalf of all purchasers of Natus Medical Incorporated (NASDAQ: BABY) common stock during the period between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”). 

If you wish to serve as a lead plaintiff, you must move the Court no later than March 31, 2017. If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.  If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.johnsonandweaver.com.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.

 

The complaint alleges that Natus and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing false and misleading statements and/or failing to disclose adverse information regarding the Company’s business and prospects, including, among other things, that: (i) the Venezuelan government had failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (ii) Natus had no means to effectively enforce its rights under its supply contract with the Venezuelan Ministry of Health (“Supply Contract”), as Venezuela was the exclusive forum for dispute resolution; (iii) Natus’s receipt of revenues pursuant to the Supply Contract was contingent on the outcome of Venezuelan elections; and (iv) as a result of the foregoing, Natus was not on track to achieve the increased guidance provided by defendants and such guidance lacked a reasonable basis. 

On January 11, 2016, Natus revealed that it expected to fall short of its fourth quarter and fiscal year 2015 guidance and disclosed that “[t]he guidance provided by the Company in October for the fourth quarter of 2015 included expected revenue of approximately $4 million under the new Venezuelan Ministry of Health contract,” but “[t]he Company was not able to ship product on the anticipated schedule because the prepayment under the contract was delayed.”  On this revelation, the price of Natus common stock declined almost $5 per share or 11%.

One month later, on February 29, 2016, Natus filed its Annual Report on Form 10-K for fiscal year 2015 with the SEC, which disclosed that elections in Venezuela and Argentina and Venezuela’s “highly inflationary economy and recessionary economic conditions” “may impact the likelihood of the Venezuelan Ministry of Health’s following through with orders under the agreement, and [Natus’s Argentinian subsidiary] ha[d] not yet received any prepayments under the agreement and no products or services ha[d] been shipped or provided.”  The Company attached a copy of the Supply Contract to the 10-K, which disclosed that $69 million in prepayments had been due by the end of 2015 and not the first quarter of 2016, as defendants had represented, and revealed that the Supply Contract was governed solely by Venezuelan law, meaning the Venezuelan government could unilaterally renege on all aspects of the agreement.

Then, on April 4, 2016, Natus issued a press release pre-announcing its preliminary first quarter 2016 results.  The release disclosed that revenue would be below the Company’s previous guidance and that Natus did not have “‘any revenue associated with the Venezuela Ministry of Health contract as [it] did not receive any prepayments during the quarter.'”  On this news, the price of Natus stock declined $7.80 per share, or nearly 20%, to close at $31.84 per share on April 4, 2016. 

Plaintiff seeks to recover damages on behalf of all purchasers of Natus common stock during the Class Period. 

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

SOURCE Johnson & Weaver, LLP

Related Links

http://johnsonandweaver.com

 

Contact Information:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

View Related News >